BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21545485)

  • 21. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
    Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiological based pharmacokinetic modeling to estimate in vivo Ki of ketoconazole on renal P-gp using human drug-drug interaction study result of fesoterodine and ketoconazole.
    Oishi M; Takano Y; Torita Y; Malhotra B; Chiba K
    Drug Metab Pharmacokinet; 2018 Feb; 33(1):90-95. PubMed ID: 29338933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
    Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
    J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
    Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
    Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
    Shoaf SE; Bricmont P; Mallikaarjun S
    Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
    Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
    Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
    Shaik MN; LaBadie RR; Rudin D; Levin WJ
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine.
    Malhotra B; Gandelman K; Sachse R; Wood N
    J Clin Pharmacol; 2009 Apr; 49(4):477-82. PubMed ID: 19246724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
    Tachibana M; Matsuki S; Maekawa Y; Kuroda K; Shimizu T; Tsutsumi J; Ishizuka H
    Clin Transl Sci; 2023 Nov; 16(11):2153-2162. PubMed ID: 37705321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.
    Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
    Br J Clin Pharmacol; 2011 Apr; 71(4):522-7. PubMed ID: 21395644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
    Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
    Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
    Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
    Ouellet D; Bramson C; Roman D; Remmers AE; Randinitis E; Milton A; Gardner M
    Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers.
    Chen X; Yang F; Zhao J; Tang Q; Heng J; Deng J; Zhang J; Chen Y; Li K; Wang J
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):141-148. PubMed ID: 34851444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers.
    Hegazy SK; Mabrouk MM; Elsisi AE; Mansour NO
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1275-80. PubMed ID: 22392555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
    Li A; Yeo K; Welty D; Rong H
    Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
    Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
    Langdon G; Davis J; Layton G; Chong CL; Weissgerber G; Vourvahis M
    Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.